CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


CamostatWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (0)


Name (Synonyms) Correlation

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D018450 Disease Progression NIH 0.26

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 A Randomised Phase II/III Trial in a Community Setting, Assessing Use of Camostat in Reducing the Clinical Progression of COVID-19 by Blocking SARS-CoV-2 Spike Protein-initiated Membrane Fusion

This is a phase II/III randomised, multi-centre, prospective, open label, community-based clinical trial. The trial aims to recruit patients who test positive for COVID-19 but who have mild disease and therefore can treat their symptoms in the community. Patients who seek testing and have a confirmed positive test result will be invited to enrol in the trial.

NCT04455815 COVID-19 Infection Drug: Camostat
MeSH:Disease Progression

Primary Outcomes

Measure: Number of participants who require hospital admission and require supplemental oxygen.

Time: Days 1-28

Secondary Outcomes

Measure: Rate of COVID-19 related hospital admission in patients with SARS-CoV-2 infection.

Time: Days 1-28 from randomisation.

Measure: Number of supplementary oxygen-free days at 28 days (from randomisation).

Time: Days 1-28 from randomisation.

Measure: Number of ventilator-free days at 28 days (from randomisation).

Time: Days 1-28 from randomisation.

Measure: To evaluate overall mortality.

Time: one year from randomisation.

Measure: Time to worst point on the scale or deterioration of two points or more (from randomisation) on a 9-point category ordinal scale.

Time: Days 1-28.


No related HPO nodes (Using clinical trials)